Molecular structure of CCT196969, CAS Number: 1163719-56-9
CCT196969 (CAS 1163719-56-9)
Alternate Names:
N-[4-[(3,4-dihydro-3-oxopyrido[2,3-b]pyrazin-8-yl)oxy]-2-fluorophenyl]-N′-[3-(1,1-dimethylethyl)-1-phenyl-1H-pyrazol-5-yl]-urea
CAS Number:
1163719-56-9
Molecular Weight:
513.5
Molecular Formula:
C27H24FN7O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
CCT196969 (CAS 1163719-56-9) References
- Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. | Girotti, MR., et al. 2015. Cancer Cell. 27: 85-96. PMID: 25500121
- Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. | Mandal, R., et al. 2016. Oncogene. 35: 2547-61. PMID: 26364606
- Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. | Kim, HS., et al. 2017. Oncogene. 36: 3334-3345. PMID: 28092667
- Reverse Phase Protein Arrays elucidate mechanisms-of-action and phenotypic response in 2D and 3D models. | Pawlak, M. and Carragher, NO. 2017. Drug Discov Today Technol. 23: 7-16. PMID: 28647089
- Advances of small molecule targeting of kinases. | Berndt, N., et al. 2017. Curr Opin Chem Biol. 39: 126-132. PMID: 28732278
- Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases. | Gampa, G., et al. 2019. J Pharmacol Exp Ther. 368: 446-461. PMID: 30622172
- A patent review of RAF kinase inhibitors (2010-2018). | Man, RJ., et al. 2019. Expert Opin Ther Pat. 29: 675-688. PMID: 31370713
- Identification of novel regulators of STAT3 activity. | Parri, E., et al. 2020. PLoS One. 15: e0230819. PMID: 32231398
- BRAF in malignant melanoma progression and metastasis: potentials and challenges. | Alqathama, A. 2020. Am J Cancer Res. 10: 1103-1114. PMID: 32368388
- CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells. | Reigstad, A., et al. 2022. PLoS One. 17: e0273711. PMID: 36084109
Inhibitor of:
ERK 1, ERK 2, Esp4, PBK, and UBE1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CCT196969, 5 mg | sc-507303 | 5 mg | $135.00 |